Overview

This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure

Status:
Terminated

Trial end date:
2014-05-01

Target enrollment:

Participant gender:

Summary

The study will evaluate the efficacy and safety of LCZ696 compared to enalapril on morbidity and mortality in patients with chronic heart failure (NYHA Class II - IV and EF =< 35%).

Phase:

Phase 3

Details

Lead Sponsor:

Novartis Pharmaceuticals

Treatments:

Enalapril
Enalaprilat
LCZ 696
Sacubitril and valsartan sodium hydrate drug combination